Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00709397 · ClinicalTrials.gov registry record
HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy
A clinical trial, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- 3
- Enrollment target
NCT00709397: Clinical Trial study, sponsored by Brigham and Women's Hospital.
NCT00709397 is a clinical trial that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00709397 was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- 3 participants
- Enrollment target
Study Summary
This study is designed to determine how quickly HIV-1 is cleared from the blood in treatment-experienced patients beginning a salvage therapy regimen that includes the integrase inhibitor raltegravir. The hypothesis is that HIV-1 is cleared as rapidly in these patients as in treatment-naive patients starting a raltegravir-based regimen.
Interventions
- OTHER blood drawing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-12 |
Why NCT00709397 stopped before completion
NCT00709397 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 3 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which blood drawing is the first listed.
NCT00709397 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00709397 about?
NCT00709397 is a clinical study titled "HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy". This study is designed to determine how quickly HIV-1 is cleared from the blood in treatment-experienced patients beginning a salvage therapy regimen that includes the integrase inhibitor raltegravir. The hypothesis is that HIV-1 is cleared as rapidly in these patients as in treatment-naive patients...
What is the current status of trial NCT00709397?
This trial is currently terminated. The enrollment target is 3 participants. The study started on 2008-06. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00709397?
The interventions under investigation include: blood drawing (OTHER).
Who is sponsoring clinical trial NCT00709397?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia